Drug intelligence / Profile preview

ESI-053

Development stage: Preclinical
Lead developer: Serina Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

ESI-053 is a **clinical-grade human embryonic stem cell line** originally developed by AgeX Therapeutics and sublicensed to ImStem Biotechnology for generation of mesenchymal stem cells used to manufacture the investigational allogeneic cell therapy IMS001. It is not a small-molecule drug or finished branded medicine; rather, it is an upstream pluripotent stem cell starting material created under current Good Manufacturing Practice conditions and used as the source for an off-the-shelf, industrially scalable MSC therapy platform. In disclosed development programs, ESI-053-derived cells underpin IMS001 programs in COVID-19, acute respiratory distress syndrome, and multiple sclerosis.

Other names: ESI 053ESI053ESI-053embryonic stem cell line ESI-053

Beyond the preview

Go deeper on ESI-053.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESI-053.

Explore the full profile